Sign in or create an account to add this stock to your watchlist.
About Ironwood Pharmaceuticals (NASDAQ:IRWD)
Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, and Macau; and a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:IRWD
CUSIP46333X10
Phone617-621-7722
Debt
Debt-to-Equity Ratio-21.52
Current Ratio4.42
Quick Ratio4.40
Price-To-Earnings
Trailing P/E Ratio-18.82
Forward P/E Ratio-28.34
P/E GrowthN/A
Sales & Book Value
Annual Sales$298.28 million
Price / Sales8.95
Cash FlowN/A
Price / CashN/A
Book Value($0.12) per share
Price / Book-146.42
Profitability
EPS (Most Recent Fiscal Year)($0.93)
Net Income$-116,930,000.00
Net Margins-34.12%
Return on Equity-2,073.20%
Return on Assets-20.90%
Miscellaneous
Employees730
Outstanding Shares151,940,000
Ironwood Pharmaceuticals (NASDAQ:IRWD) Frequently Asked Questions
What is Ironwood Pharmaceuticals' stock symbol?
Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."
How were Ironwood Pharmaceuticals' earnings last quarter?
Ironwood Pharmaceuticals (NASDAQ:IRWD) announced its quarterly earnings results on Tuesday, May, 1st. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.06. The biotechnology company had revenue of $69.16 million for the quarter, compared to the consensus estimate of $78.65 million. Ironwood Pharmaceuticals had a negative net margin of 34.12% and a negative return on equity of 2,073.20%. The company's revenue for the quarter was up 32.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.33) earnings per share. View Ironwood Pharmaceuticals' Earnings History.
When is Ironwood Pharmaceuticals' next earnings date?
What price target have analysts set for IRWD?
10 analysts have issued 1-year price targets for Ironwood Pharmaceuticals' stock. Their forecasts range from $13.00 to $25.00. On average, they expect Ironwood Pharmaceuticals' stock price to reach $18.60 in the next twelve months. View Analyst Ratings for Ironwood Pharmaceuticals.
Are investors shorting Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals saw a decline in short interest in the month of May. As of May 15th, there was short interest totalling 18,814,070 shares, a decline of 12.2% from the April 30th total of 21,438,253 shares. Based on an average daily volume of 1,695,797 shares, the days-to-cover ratio is currently 11.1 days. Currently, 13.7% of the company's stock are short sold.
Who are some of Ironwood Pharmaceuticals' key competitors?
Some companies that are related to Ironwood Pharmaceuticals include Perrigo (PRGO), BeiGene (BGNE), Jazz Pharmaceuticals (JAZZ), Alnylam Pharmaceuticals (ALNY), Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), GALAPAGOS NV/S (GLPG), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), Dr. Reddy's Laboratories (RDY) and United Therapeutics (UTHR).
Who are Ironwood Pharmaceuticals' key executives?
Ironwood Pharmaceuticals' management team includes the folowing people:
- Dr. Peter M. Hecht, Co-Founder, CEO & Director (Age 54)
- Dr. Mark G. Currie, Chief Scientific Officer, Pres of R&D and Sr. VP (Age 63)
- Ms. Halley E. Gilbert, Sr. VP, Chief Legal Officer & Sec. (Age 48)
- Mr. Thomas A. McCourt, Sr. VP of Marketing & Sales and Chief Commercial Officer (Age 61)
- Mr. Brian M. Cali Ph.D., Co-Founder and Sr. VP of R&D Strategy & External Innovation
Has Ironwood Pharmaceuticals been receiving favorable news coverage?
Press coverage about IRWD stock has been trending somewhat positive on Thursday, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ironwood Pharmaceuticals earned a media sentiment score of 0.14 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 46.39 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are Ironwood Pharmaceuticals' major shareholders?
Ironwood Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (3.65%), OppenheimerFunds Inc. (1.70%), Northern Trust Corp (1.03%), Loomis Sayles & Co. L P (1.01%), Sector Gamma AS (0.74%) and Schwab Charles Investment Management Inc. (0.45%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals.
Which major investors are selling Ironwood Pharmaceuticals stock?
IRWD stock was sold by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, Artal Group S.A., State of Wisconsin Investment Board, Barclays PLC, Sector Gamma AS, Loomis Sayles & Co. L P, California Public Employees Retirement System and Russell Investments Group Ltd.. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Gina Consylman, Halley E Gilbert, Julie Mchugh, Mark G Currie and Peter M Hecht. View Insider Buying and Selling for Ironwood Pharmaceuticals.
Which major investors are buying Ironwood Pharmaceuticals stock?
IRWD stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, OppenheimerFunds Inc., UBS Group AG, Engineers Gate Manager LP, Point72 Asset Management L.P., Trexquant Investment LP, Schwab Charles Investment Management Inc. and Alps Advisors Inc.. View Insider Buying and Selling for Ironwood Pharmaceuticals.
How do I buy shares of Ironwood Pharmaceuticals?
Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ironwood Pharmaceuticals' stock price today?
One share of IRWD stock can currently be purchased for approximately $17.57.
How big of a company is Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals has a market capitalization of $2.66 billion and generates $298.28 million in revenue each year. The biotechnology company earns $-116,930,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis. Ironwood Pharmaceuticals employs 730 workers across the globe.
How can I contact Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]
MarketBeat Community Rating for Ironwood Pharmaceuticals (IRWD)
MarketBeat's community ratings are surveys of what our community members think about Ironwood Pharmaceuticals and other stocks. Vote "Outperform" if you believe IRWD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRWD will underperform the S&P 500 over the long term. You may vote once every thirty days.
Ironwood Pharmaceuticals (NASDAQ:IRWD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Ironwood Pharmaceuticals in the last 12 months. Their average twelve-month price target is $18.60, suggesting that the stock has a possible upside of 5.86%. The high price target for IRWD is $25.00 and the low price target for IRWD is $13.00. There are currently 2 sell ratings, 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Buy |
| Consensus Rating Score: | 2.27 | 2.30 | 2.30 | 2.50 |
| Ratings Breakdown: | 2 Sell Rating(s)
4 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $18.60 | $18.1250 | $17.75 | $18.2857 |
| Price Target Upside: | 5.86% upside | 2.00% upside | 16.78% upside | 22.56% upside |
Ironwood Pharmaceuticals (NASDAQ:IRWD) Consensus Price Target History
Ironwood Pharmaceuticals (NASDAQ:IRWD) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Ironwood Pharmaceuticals (NASDAQ:IRWD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Ironwood Pharmaceuticals (NASDAQ IRWD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.63%
Ironwood Pharmaceuticals (NASDAQ IRWD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/5/2018 | Julie Mchugh | Director | Sell | 1,500 | $14.06 | $21,090.00 | 77,908 |  |
| 2/21/2018 | Gina Consylman | CFO | Sell | 3,594 | $14.66 | $52,688.04 | 59,125 | |
| 2/21/2018 | Mark G Currie | Insider | Sell | 1,634 | $14.66 | $23,954.44 | 18,124 | |
| 1/24/2018 | Mark G Currie | Insider | Sell | 60,000 | $15.45 | $927,000.00 | 835,000 | |
| 12/7/2017 | Peter M Hecht | CEO | Sell | 113,405 | $15.12 | $1,714,683.60 | 4,696,917 | |
| 12/4/2017 | Julie Mchugh | Director | Sell | 1,500 | $16.45 | $24,675.00 | 79,408 | |
| 11/10/2017 | Gina Consylman | CFO | Sell | 864 | $15.20 | $13,132.80 | | |
| 9/5/2017 | Julie Mchugh | Director | Sell | 1,500 | $16.16 | $24,240.00 | 80,908 | |
| 8/18/2017 | Gina Consylman | Insider | Sell | 207 | $14.34 | $2,968.38 | 52,865 | |
| 6/22/2017 | Halley E Gilbert | Insider | Sell | 35,000 | $19.75 | $691,250.00 | 35,000 | |
| 5/15/2017 | Thomas A Mccourt | Insider | Sell | 30,000 | $18.20 | $546,000.00 | 30,000 | |
| 2/14/2017 | Halley E Gilbert | Insider | Sell | 37,385 | $16.75 | $626,198.75 | 37,385 | |
| 1/12/2017 | Peter M Hecht | CEO | Sell | 65,987 | $15.67 | $1,034,016.29 | 4,703,315 | |
| 12/5/2016 | Lawrence S Olanoff | Director | Sell | 3,200 | $15.68 | $50,176.00 | 26,105 | |
| 9/6/2016 | Lawrence S Olanoff | Director | Sell | 3,200 | $13.72 | $43,904.00 | 29,305 | |
| 8/19/2016 | Gina Consylman | Insider | Sell | 207 | $13.54 | $2,802.78 | 21,123 | |
| 6/3/2016 | Lawrence S Olanoff | Director | Sell | 2,200 | $12.92 | $28,424.00 | 32,505 | |
| 5/25/2016 | Halley E Gilbert | Insider | Sell | 20,275 | $12.19 | $247,152.25 | 5,865 | |
| 3/11/2016 | Peter M Hecht | CEO | Sell | 120,000 | $10.72 | $1,286,400.00 | 4,710,322 | |
| 3/7/2016 | Lawrence S Olanoff | Director | Sell | 2,200 | $11.11 | $24,442.00 | 11,031 | |
| 2/24/2016 | Edward P Owens | Director | Buy | 10,000 | $8.32 | $83,200.00 | 144,006 | |
| 2/24/2016 | Gina Consylman | CAO | Sell | 420 | $8.50 | $3,570.00 | 6,330 | |
| 2/24/2016 | Mark G Currie | Insider | Sell | 152,154 | $8.53 | $1,297,873.62 | 25,558 | |
| 2/24/2016 | Thomas Graney | CFO | Sell | 563 | $8.50 | $4,785.50 | 5,137 | |
| 12/15/2015 | Peter M. Hecht | CEO | Sell | 73,418 | $11.07 | $812,737.26 | | |
| 12/7/2015 | Lawrence S Olanoff | Director | Sell | 2,200 | $11.77 | $25,894.00 | 13,231 | |
| 9/4/2015 | Lawrence S Olanoff | Director | Sell | 3,725 | $10.97 | $40,863.25 | 15,431 | |
| 3/17/2015 | Peter M Hecht | CEO | Sell | 200,000 | $15.62 | $3,124,000.00 | | |
| 3/12/2015 | Joseph C Cook Jr | Director | Sell | 5,883 | $15.54 | $91,421.82 | | |
| 3/10/2015 | Bryan E Roberts | Director | Sell | 95,998 | $15.20 | $1,459,169.60 | | |
| 3/3/2015 | Peter M Hecht | CEO | Sell | 63,442 | $15.75 | $999,211.50 | | |
| 2/20/2015 | Joseph C Cook Jr | Director | Sell | 35,500 | $15.60 | $553,800.00 | | |
| 12/15/2014 | Bryan E Roberts | Director | Sell | 19,792 | $15.20 | $300,838.40 | | |
| 6/12/2014 | Bryan E Roberts | Director | Sell | 200,000 | $14.24 | $2,848,000.00 | | |
| 5/29/2014 | Michael J Higgins | COO | Sell | 50,000 | $14.56 | $728,000.00 | | |
| 5/22/2014 | Mark Currie | Insider | Sell | 25,000 | $13.93 | $348,250.00 | 2,166 | |
| 4/24/2014 | Mark Currie | Insider | Sell | 25,000 | $11.67 | $291,750.00 | 2,166 | |
| 1/23/2014 | Mark Currie | Insider | Sell | 20,000 | $14.38 | $287,600.00 | 2,166 | |
| 1/14/2014 | Bryan Roberts | Director | Sell | 21,200 | $12.57 | $266,484.00 | | |
| 1/13/2014 | Bryan Roberts | Director | Sell | 823,350 | $12.71 | $10,464,778.50 | | |
| 1/6/2014 | Bryan Roberts | Director | Sell | 55,450 | $12.01 | $665,954.50 | | |
| 11/7/2013 | Terrance Mcguire | Director | Sell | 2,083 | $9.11 | $18,976.13 | 2,915 | |
| 6/17/2013 | Michael J Higgins | COO | Sell | 150,000 | $11.74 | $1,761,000.00 | | |
| 3/11/2013 | Thomas A Mccourt | Insider | Sell | 40,000 | $17.00 | $680,000.00 | | |
| 11/5/2012 | Peter M Hecht | CEO | Buy | 50,000 | $11.65 | $582,500.00 | | |
| 10/8/2012 | Fmr Llc | Insider | Sell | 19,305 | $13.02 | $251,351.10 | | |
(Data available from 1/1/2013 forward)
Ironwood Pharmaceuticals (NASDAQ IRWD) News Headlines
| Source: |
|
Ironwood Pharmaceuticals (NASDAQ:IRWD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Ironwood Pharmaceuticals (NASDAQ:IRWD) Income Statement, Balance Sheet and Cash Flow Statement
Ironwood Pharmaceuticals (NASDAQ IRWD) Stock Chart for Thursday, May, 24, 2018
Loading chart…
